| Literature DB >> 31850754 |
John Y L Chung, Dongfang Meng, Michael Shevlin, Venugopal Gudipati, Qinghao Chen, Yizhou Liu, Yu-Hong Lam, Aaron Dumas, Jeremy Scott, Qiang Tu, Feng Xu.
Abstract
Relebactam, a potent β-lactamase inhibitor, in combination with Primaxin is an FDA-approved (Recarbrio) treatment for serious and antibiotic-resistant bacterial infections. An efficient synthesis of key chiral piperidine intermediate 1 suitable for large-scale preparation of relebactam is described. The key steps include a unique highly diastereoselective FeCl3·6H2O/NaBH4 reduction of a chiral oxime ether and chemoselective amidation of the resulting unprotected pipecolic acid. Nuclear magnetic resonance studies and density functional theory calculations were carried out on the substrate-Fe(III) complexes, which shed light on diastereoselective reduction.Entities:
Year: 2020 PMID: 31850754 DOI: 10.1021/acs.joc.9b02948
Source DB: PubMed Journal: J Org Chem ISSN: 0022-3263 Impact factor: 4.354